Related studies

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, and more

RECRUITINGPhase 2

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

NCT07088211 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

RECRUITINGPhase 1/2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972 · HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, and more

RECRUITINGPhase 1

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760 · Solid Tumor, Advanced Cancer, and more

RECRUITING

Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention

NCT06821243 · Squamous Cell Carcinoma of Oropharynx

View all related studies →

Patient Perspectives in Squamous Cell Carcinoma Clinical Trials

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention

Trial snapshot

Condition

Locations shown

For caregivers